



Reducing Financial Burden and Financial Risk: Example of Tuberculosis Treatment in India

Dean T. Jamison

University of Washington, Department of Global Health
Harvard Program in Ethics and Health
April 18, 2013



Plan for this Talk

Conceptual background

Universal public finance of TB treatment of India



TB Treatment in India

Joint work with Stéphane Verguet and Ramanan Laxminarayan



From Cost-Effectiveness Analysis (CEA) to Extended Cost-Effectiveness Analysis (ECEA)

Traditional economic evaluation focus (CEA)

Cost-effectiveness of technical health interventions (e.g. antiretroviral therapy for HIV/AIDS)

Policymaking focus (ECEA)

Resources allocated across different options

- 1) Health interventions
- 2) Health service delivery platforms
- 3) Health policy levers (e.g. universal public finance)



Specific Consequences of universal public finance (UPF)

- Health gains (burden of disease averted)
- Financial consequences for household expenditures

UPF "crowds out" medical expenses privately financed


- Financial protection benefits
 UPF provides "insurance" to households from medical impoverishment
- Distributional consequences (across income groups)



ECEA Measures of UPF

economic evaluation for health

UPF for an intervention (e.g. TB treatment)





Tuberculosis in India

economic evaluation for health

TB epidemiology

Annual incidence of 170 per 100,000 (WHO 2010)
4 times higher incidence among the poor (Muniyandi et al. 2007)
Case fatality rate of 0.25 (Corbett et al. 2003)

TB treatment (DOTS)

Cost of \$80 per patient Effective at 90% (WHO 2010)


TB treatment demand

Individuals with:

- low income do not buy DOTS
- higher income purchase DOTS (80%)



UPF for TB Treatment Over 1 Year for 1 Million Indians





Financial Protection Benefits Due to UPF (1)

Risk aversion

Individuals value protection from the risk of uncertain adverse events

y = individual income

r = coefficient of relative risk aversion

Approach consistent with recent work

McClellan & Skinner. The incidence of Medicare.

Journal of Public Economics 2006

Smith. Incorporating financial protection into the economic evaluation of health technologies. Health Economics 2012




Financial Protection Benefits Due to UPF (2)

- Money-metric value of insurance provided
 - Gamble with:
 - disease occurs at incidence p (depending on income)
 - has treatment cost c

- For 1 individual, money-metric value of insurance
 - = expected value certainty equivalent of gamble



Financial Protection Benefits with UPF for TB Treatment over 1 Year for 1 Million Indians



4/25/2013

Total financial protection value of \$10,000



Benefits over 1 Year for 1 Million Indians with UPF for TB Treatment

	Outcome	Total	Income Quintile I (Poorest)	Income Quintile II (Poorer)	Income Quintile III (Middle)	Income Quintile IV (Richer)	Income Quintile V (Richest)
1	TB deaths averted	150	100	50	0	0	0
2	Private expenditures crowded out	\$70,000	0	15,000	25,000	20,000	10,000
3	Money- metric value of insurance	\$10,000	0	3,000	4,000	2,000	1,000

Total cost of public program of \$130,000



Coping Mechanisms: Borrowing


- Without UPF, when faced with costly treatment, the poor borrow from peers or sell assets
- 50% of poor households in India borrow money/sell assets at high interest rates (Kruk et al. 2009)
- Assume the poor take a loan over 10 years at annual interest rate of 20% to subsidize TB treatment




Benefits Over 1 Year for 1 Million Indians with UPF for TB Treatment

(with borrowing)









Borrowing: A Substitute to UPF?

economic evaluation for health

 Financial protection could be provided through mechanisms reducing cost of borrowing

e.g. institutional arrangements to allow improved borrowing interest rate



- Effective substitute for UPF in averting TB deaths
- Lowers costs to the public sector

But burdens the poor with heavy debt



Conclusions (1)

ECEAs

 incorporate equity & financial protection, two important objectives of health systems (Murray & Frenk 2000)


Case study: UPF of TB treatment in India

- health gains concentrated among poor
- financial protection benefits concentrated among poor, effectively replacing coping mechanisms
- crowding out of bad treatment options = enhances quality



Conclusions (2): ECEA Output

Health & financial risk protection benefits afforded, per \$100,000 spent





Thank you

Contact Information: Djamison@uw.edu